初步经皮冠状动脉介入治疗中早期应用肝素对冠状动脉血流的影响

IF 0.6 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Shutian Shi, Lei Zhen, Mei Wang, Chunmei Wang, Hui Ai, Bin Que, Shaoping Nie
{"title":"初步经皮冠状动脉介入治疗中早期应用肝素对冠状动脉血流的影响","authors":"Shutian Shi, Lei Zhen, Mei Wang, Chunmei Wang, Hui Ai, Bin Que, Shaoping Nie","doi":"10.4314/tjpr.v22i8.21","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the efficacy and safety of unfractionated heparin (UFH) anticoagulant administered upstream in the ambulance or emergency room during primary percutaneous coronary intervention (pPCI) for patients with acute ST-segment elevation myocardial infarction (STEMI).Methods: The study included STEMI patients who received either early UFH subcutaneously (SC) (n = 163) or intraoperative UFH (SC) during pPCI (n = 476) between January 2017 to August 2018. Baseline characteristics, infarct-related artery (IRA) status, and procedural characteristics were analyzed. The primary endpoint was thrombolysis in myocardial infarction (TIMI) flow grade 2 - 3 before intervention. The secondary endpoints were time from first medical contact to guidewire passage, postoperative TIMI 3 flow grade, acute stent thrombosis, and in-hospital bleeding events.Results: Baseline characteristics were similar between the groups, with no significant difference in IRA location. Both groups underwent coronary angiography, with most patients receiving pPCI. The primary endpoint occurred in 18.1 % of patients in intraoperative UFH group and 27.6 % in the early UFH group, with a significant difference between the groups (p < 0.05). There was no significant difference in postoperative TIMI 3 flow grade or acute stent thrombosis, but bleeding events (BARC 2-5) were similar between groups (1.1 % in intraoperative group and 1.8 % in early UFH group, p > 0.05)Conclusion: Early upstream administration of UFH anticoagulation in STEMI patients improves coronary artery potency before pPCI, and early use of fixed-dose UFH is safe and does not increase major bleeding complications.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"43 1","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of early application of heparin on coronary blood flow during primary percutaneous coronary intervention\",\"authors\":\"Shutian Shi, Lei Zhen, Mei Wang, Chunmei Wang, Hui Ai, Bin Que, Shaoping Nie\",\"doi\":\"10.4314/tjpr.v22i8.21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To investigate the efficacy and safety of unfractionated heparin (UFH) anticoagulant administered upstream in the ambulance or emergency room during primary percutaneous coronary intervention (pPCI) for patients with acute ST-segment elevation myocardial infarction (STEMI).Methods: The study included STEMI patients who received either early UFH subcutaneously (SC) (n = 163) or intraoperative UFH (SC) during pPCI (n = 476) between January 2017 to August 2018. Baseline characteristics, infarct-related artery (IRA) status, and procedural characteristics were analyzed. The primary endpoint was thrombolysis in myocardial infarction (TIMI) flow grade 2 - 3 before intervention. The secondary endpoints were time from first medical contact to guidewire passage, postoperative TIMI 3 flow grade, acute stent thrombosis, and in-hospital bleeding events.Results: Baseline characteristics were similar between the groups, with no significant difference in IRA location. Both groups underwent coronary angiography, with most patients receiving pPCI. The primary endpoint occurred in 18.1 % of patients in intraoperative UFH group and 27.6 % in the early UFH group, with a significant difference between the groups (p < 0.05). There was no significant difference in postoperative TIMI 3 flow grade or acute stent thrombosis, but bleeding events (BARC 2-5) were similar between groups (1.1 % in intraoperative group and 1.8 % in early UFH group, p > 0.05)Conclusion: Early upstream administration of UFH anticoagulation in STEMI patients improves coronary artery potency before pPCI, and early use of fixed-dose UFH is safe and does not increase major bleeding complications.\",\"PeriodicalId\":23347,\"journal\":{\"name\":\"Tropical Journal of Pharmaceutical Research\",\"volume\":\"43 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tropical Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/tjpr.v22i8.21\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Journal of Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/tjpr.v22i8.21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨急性st段抬高型心肌梗死(STEMI)患者首次经皮冠状动脉介入治疗(pPCI)期间,在救护车或急诊室上游给予未分级肝素(UFH)抗凝剂的有效性和安全性。方法:该研究包括2017年1月至2018年8月期间接受早期皮下UFH (n = 163)或pPCI期间术中UFH (n = 476)的STEMI患者。分析基线特征、梗死相关动脉(IRA)状态和手术特征。主要终点是干预前心肌梗死(TIMI)血流2 - 3级溶栓。次要终点是从第一次医疗接触到导丝通过的时间、术后TIMI 3血流等级、急性支架血栓形成和院内出血事件。结果:两组间基线特征相似,IRA位置无显著差异。两组患者均行冠状动脉造影,多数患者接受pPCI。术中UFH组患者出现主要终点的比例为18.1%,早期UFH组患者出现主要终点的比例为27.6%,两组间差异有统计学意义(p <0.05)。术后TIMI 3血流等级和急性支架血栓形成无显著差异,但两组间出血事件(BARC 2-5)相似(术中组1.1%,早期UFH组1.8%,p >0.05)结论:STEMI患者在pPCI前早期上游给予UFH抗凝治疗可提高冠状动脉效力,早期使用固定剂量UFH是安全的,不会增加重大出血并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of early application of heparin on coronary blood flow during primary percutaneous coronary intervention
Purpose: To investigate the efficacy and safety of unfractionated heparin (UFH) anticoagulant administered upstream in the ambulance or emergency room during primary percutaneous coronary intervention (pPCI) for patients with acute ST-segment elevation myocardial infarction (STEMI).Methods: The study included STEMI patients who received either early UFH subcutaneously (SC) (n = 163) or intraoperative UFH (SC) during pPCI (n = 476) between January 2017 to August 2018. Baseline characteristics, infarct-related artery (IRA) status, and procedural characteristics were analyzed. The primary endpoint was thrombolysis in myocardial infarction (TIMI) flow grade 2 - 3 before intervention. The secondary endpoints were time from first medical contact to guidewire passage, postoperative TIMI 3 flow grade, acute stent thrombosis, and in-hospital bleeding events.Results: Baseline characteristics were similar between the groups, with no significant difference in IRA location. Both groups underwent coronary angiography, with most patients receiving pPCI. The primary endpoint occurred in 18.1 % of patients in intraoperative UFH group and 27.6 % in the early UFH group, with a significant difference between the groups (p < 0.05). There was no significant difference in postoperative TIMI 3 flow grade or acute stent thrombosis, but bleeding events (BARC 2-5) were similar between groups (1.1 % in intraoperative group and 1.8 % in early UFH group, p > 0.05)Conclusion: Early upstream administration of UFH anticoagulation in STEMI patients improves coronary artery potency before pPCI, and early use of fixed-dose UFH is safe and does not increase major bleeding complications.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.00
自引率
33.30%
发文量
490
审稿时长
4-8 weeks
期刊介绍: We seek to encourage pharmaceutical and allied research of tropical and international relevance and to foster multidisciplinary research and collaboration among scientists, the pharmaceutical industry and the healthcare professionals. We publish articles in pharmaceutical sciences and related disciplines (including biotechnology, cell and molecular biology, drug utilization including adverse drug events, medical and other life sciences, and related engineering fields). Although primarily devoted to original research papers, we welcome reviews on current topics of special interest and relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信